Curis Lifesciences Ltd

Fri 4/09/2026,15:32:3 | NSE : CURIS

₹151.356.25 (4.31%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 145.70

Previous Close

₹ 145.10

Volume

38000

Mkt Cap ( ₹ Cr)

₹ 122.36

High

₹ 153.50

Low

₹ 145.00

52 Week High

₹ 153.50

52 Week Low

₹ 83.60

Book Value Per Share

₹ 58.58

Dividend Yield

₹ 0.00

Face Value

₹₹10.00

What's Your Call?

Collective community sentiment on Curis Lifesciences Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Curis Lifesciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Curis Lifesciences - Resignation of Director/KMP/SMP

    3 Sep 2026, 7:15PM Curis Lifesciences Limited has informed the Exchange about Resignation of Director/KMP/SMP
  • Curis Lifesciences - Cessation

    3 Sep 2026, 7:13PM Curis Lifesciences Limited has informed the Exchange regarding Cessation of Mr Nikhil Purohit as Company Secretary & Compliance Officer of the company
  • Curis Lifesciences - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    19 Aug 2026, 7:12PM Curis Lifesciences Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 201
  • Curis Lifesciences - Agreements

    13 Aug 2026, 7:01PM Curis Lifesciences Limited has informed the Exchange about Joint venture agreement entered into by the company with CUROSUN PHARMACEUTICAL NIG LTD (N
  • Curis Lifesciences - Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter

    15 Jul 2026, 11:56AM Curis Lifesciences Limited has informed regarding Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requiremen
  • Curis Lifesciences - General Updates

    13 Jul 2026, 7:28PM Curis Lifesciences Limited has informed the Exchange about Comments of board on the fine levied by the National Stock Exchange (NSE Limited)
  • Curis Lifesciences - Appointment

    13 Jul 2026, 7:24PM Curis Lifesciences Limited has informed the Exchange regarding Appointment of Mr Devabhai Hamirbhai Jadeja as Non- Executive Independent Director of
  • Curis Lifesciences - Reply to Clarification- Financial results

    9 Jul 2026, 11:52AM The Exchange had sought clarification from Curis Lifesciences Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Lis
  • Curis Lifesciences - Resignation of Director/KMP/SMP

    3 Jul 2026, 7:58PM Curis Lifesciences Limited has informed the Exchange about Resignation of Director/KMP/SMP
  • Curis Lifesciences - Resignation of Director/KMP/SMP

    3 Jul 2026, 7:48PM Curis Lifesciences Limited has informed the Exchange about Resignation of Director/KMP/SMP
  • Curis Lifesciences - Cessation

    3 Jul 2026, 6:31PM Curis Lifesciences Limited has informed the Exchange regarding Cessation of Mr. Chand Rameshbhai Kanabar as Non- Executive Independent Director of th
  • Curis Lifesciences - General Updates

    1 Jul 2026, 4:19PM Curis Lifesciences Limited has informed the Exchange about General Updates
  • Curis Lifesciences - Clarification - Financial Results

    29 Jun 2026, 9:39AM The Exchange has sought clarification from Curis Lifesciences Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Lis
  • Curis Lifesciences - Press Release

    23 Jun 2026, 6:11PM Curis Lifesciences Limited has informed the Exchange regarding a press release dated Jun 23, 2026, titled ""Press Release pertaining to audited financ

Key fundamentals

Evaluate the intrinsic value of Curis Lifesciences Ltd stock 

Name March-26 March-25 March-24
Assets 68.9486 31.8451 22.9618
Liabilities 68.9486 31.8451 22.9618
Equity 8.0844 5.9344 0.5
Gross Profit 11.1294 9.5373 8.3876
Net Profit 6.9163 6.1051 4.867
Cash From Operating Activities -16.416 -1.7625 0.28
NPM(%) 11.4 12.42 13.68
Revenue 60.6288 49.1323 35.5557
Expenses 49.4994 39.595 27.1681
ROE(%) 14.6 12.89 10.27

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Curis Lifesciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 860.25 -1.14 21.76 0.00 -26.19 0.58
Lotus Eye Hospital and Institute Ltd 109.43 0.14 1563.29 0.00 0.39 0.00
Vaishali Pharma Ltd 8.32 -0.48 26.00 0.00 15.42 0.00
Astec Lifesciences Ltd 554.45 -3.28 0.00 0.00 -363.14 0.00

Company Info

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceutacals", pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation datedMarch 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. From year 2010 to 2016, our partnership firm was engaged in the marketing and trading of various pharmaceutical products. As a partnership firm, our product portfolio included tablets, capsules, oral liquids, creams, ointments, injections, lotions, oral powders and other nutraceuticals products. We procured finished goods from manufacturers and distributed them to various wholesalers and other clients throught the country.MAJOR EVENTS:2011- Started Business by starting a Partnership Firm with two Partners in name of "M/s Loreto Pharmaceutical" by Mr. Dasharathbhai Patel and Mr. Piyush Gordhanbhai Antala.2016- The Partnership Firm got converted into Private Company post conversion and receiving Certificate of Incorporation on March 23rd, 2016.2018- The Company received FDA License for manufacturing Pharma products.2019- The Company availed Kenya PPC board approval and approval from Ministry of Health - Republic of Yemen, State Good Manufacturing Practices and GLP licence from Local FDA 2020- The Company received WHO GMP certificate.2021- The Company received FDA Approval from Philippines during the tragic era of COVID-192022- Renewal of the WHO Certificates and Nigeria NAFDAC Approval2023- Retention of FDA License for manufacturing Pharma products.2025- Conversion From Private Limited into Public Limited company.

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceutacals", pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation datedMarch 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. From year 2010 to 2016, our partnership firm was engaged in the marketing and trading of various pharmaceutical products. As a partnership firm, our product portfolio included tablets, capsules, oral liquids, creams, ointments, injections, lotions, oral powders and other nutraceuticals products. We procured finished goods from manufacturers and distributed them to various wholesalers and other clients throught the country.MAJOR EVENTS:2011- Started Business by starting a Partnership Firm with two Partners in name of "M/s Loreto Pharmaceutical" by Mr. Dasharathbhai Patel and Mr. Piyush Gordhanbhai Antala.2016- The Partnership Firm got converted into Private Company post conversion and receiving Certificate of Incorporation on March 23rd, 2016.2018- The Company received FDA License for manufacturing Pharma products.2019- The Company availed Kenya PPC board approval and approval from Ministry of Health - Republic of Yemen, State Good Manufacturing Practices and GLP licence from Local FDA 2020- The Company received WHO GMP certificate.2021- The Company received FDA Approval from Philippines during the tragic era of COVID-192022- Renewal of the WHO Certificates and Nigeria NAFDAC Approval2023- Retention of FDA License for manufacturing Pharma products.2025- Conversion From Private Limited into Public Limited company.

Parent Organisation

Curis Lifesciences Ltd.

Founded

23/03/2016

Managing Director

Mr.Dharmesh Dasharathbhai Patel

NSE Symbol

CURISSM

FAQ